Copper-dependent Inhibition of Human Cytochrome C Oxidase by a Dimeric Conformer of Amyloid-beta1-42

Overview

Journal J Neurosci

Specialty Neurology

Date 2005 Jan 22

PMID 15659604

Citations 138

Authors

Peter J Crouch

Rachel Blake

James A Duce

Giuseppe D Ciccotosto

Qiao-Xin Li

Kevin J Barnham

Cyril C Curtain

Robert A Cherny

Roberto Cappai

Thomas Dyrks

Colin L Masters

Ian A Trounce

Affiliations

Soon will be listed here.

Abstract

In studies of Alzheimer's disease pathogenesis there is an increasing focus on mechanisms of intracellular amyloid-beta (Abeta) generation and toxicity. Here we investigated the inhibitory potential of the 42 amino acid Abeta peptide (Abeta1-42) on activity of electron transport chain enzyme complexes in human mitochondria. We found that synthetic Abeta1-42 specifically inhibited the terminal complex cytochrome c oxidase (COX) in a dose-dependent manner that was dependent on the presence of Cu2+ and specific "aging" of the Abeta1-42 solution. Maximal COX inhibition occurred when using Abeta1-42 solutions aged for 3-6 h at 30 degrees C. The level of Abeta1-42-mediated COX inhibition increased with aging time up to approximately 6 h and then declined progressively with continued aging to 48 h. Photo-induced cross-linking of unmodified proteins followed by SDS-PAGE analysis revealed dimeric Abeta as the only Abeta species to provide significant temporal correlation with the observed COX inhibition. Analysis of brain and liver from an Alzheimer's model mouse (Tg2576) revealed abundant Abeta immunoreactivity within the brain mitochondria fraction. Our data indicate that endogenous Abeta is associated with brain mitochondria and that Abeta1-42, possibly in its dimeric conformation, is a potent inhibitor of COX, but only when in the presence of Cu2+. We conclude that Cu2+-dependent Abeta-mediated inhibition of COX may be an important contributor to the neurodegeneration process in Alzheimer's disease.

Citing Articles

Mitochondrial pathways of copper neurotoxicity: focus on mitochondrial dynamics and mitophagy.

Aschner M, Skalny A, Lu R, Martins A, Tizabi Y, Nekhoroshev S Front Mol Neurosci. 2024; 17:1504802.

PMID: 39703721 PMC: 11655512. DOI: 10.3389/fnmol.2024.1504802.

Neurotoxic β-amyloid oligomers cause mitochondrial dysfunction-the trigger for PANoptosis in neurons.

Meng X, Song Q, Liu Z, Liu X, Wang Y, Liu J Front Aging Neurosci. 2024; 16:1400544.

PMID: 38808033 PMC: 11130508. DOI: 10.3389/fnagi.2024.1400544.

Mitochondrial Complex I and β-Amyloid Peptide Interplay in Alzheimer's Disease: A Critical Review of New and Old Little Regarded Findings.

Atlante A, Valenti D Int J Mol Sci. 2023; 24(21).

PMID: 37958934 PMC: 10650435. DOI: 10.3390/ijms242115951.

Photo-Induced Cross-Linking of Unmodified α-Synuclein Oligomers.

Ortigosa-Pascual L, Leiding T, Linse S, Palmadottir T ACS Chem Neurosci. 2023; 14(17):3192-3205.

PMID: 37621159 PMC: 10485903. DOI: 10.1021/acschemneuro.3c00326.

Systematic review of P-magnetic resonance spectroscopy studies of brain high energy phosphates and membrane phospholipids in aging and Alzheimer's disease.

Jett S, Boneu C, Zarate C, Carlton C, Kodancha V, Nerattini M Front Aging Neurosci. 2023; 15:1183228.

PMID: 37273652 PMC: 10232902. DOI: 10.3389/fnagi.2023.1183228.

References

Galeazzi L, Ronchi P, Franceschi C, Giunta S . In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1-42) through dityrosine bridge formation. Amyloid. 1999; 6(1):7-13. DOI: 10.3109/13506129908993282. View

Fancy D, Kodadek T . Chemistry for the analysis of protein-protein interactions: rapid and efficient cross-linking triggered by long wavelength light. Proc Natl Acad Sci U S A. 1999; 96(11):6020-4. PMC: 26828. DOI: 10.1073/pnas.96.11.6020. View

Canevari L, Clark J, Bates T . beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett. 1999; 457(1):131-4. DOI: 10.1016/s0014-5793(99)01028-5. View

Hartley D, Walsh D, Ye C, Diehl T, Vasquez S, Vassilev P . Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci. 1999; 19(20):8876-84. PMC: 6782787. View

McLean C, Cherny R, Fraser F, Fuller S, Smith M, Beyreuther K . Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999; 46(6):860-6. DOI: 10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m. View

Huang X, Cuajungco M, Atwood C, Hartshorn M, Tyndall J, Hanson G . Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem. 1999; 274(52):37111-6. DOI: 10.1074/jbc.274.52.37111. View

Anderson M, Sims N . Improved recovery of highly enriched mitochondrial fractions from small brain tissue samples. Brain Res Brain Res Protoc. 2000; 5(1):95-101. DOI: 10.1016/s1385-299x(99)00060-4. View

Naslund J, Haroutunian V, Mohs R, Davis K, Davies P, Greengard P . Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000; 283(12):1571-7. DOI: 10.1001/jama.283.12.1571. View

Maurer I, Zierz S, Moller H . A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging. 2000; 21(3):455-62. DOI: 10.1016/s0197-4580(00)00112-3. View

10.

Parks J, Smith T, Trimmer P, Bennett Jr J, Parker Jr W . Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem. 2001; 76(4):1050-6. DOI: 10.1046/j.1471-4159.2001.00112.x. View

11.

CURTAIN C, Ali F, Volitakis I, Cherny R, Norton R, Beyreuther K . Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem. 2001; 276(23):20466-73. DOI: 10.1074/jbc.M100175200. View

12.

Selkoe D . Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001; 81(2):741-66. DOI: 10.1152/physrev.2001.81.2.741. View

13.

Hirai K, Aliev G, Nunomura A, Fujioka H, Russell R, Atwood C . Mitochondrial abnormalities in Alzheimer's disease. J Neurosci. 2001; 21(9):3017-23. PMC: 6762571. View

14.

Bitan G, Lomakin A, Teplow D . Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem. 2001; 276(37):35176-84. DOI: 10.1074/jbc.M102223200. View

15.

Cottrell D, Blakely E, Johnson M, Ince P, Turnbull D . Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology. 2001; 57(2):260-4. DOI: 10.1212/wnl.57.2.260. View

16.

Wang H, Pasternak J, Kuo H, Ristic H, Lambert M, Chromy B . Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2001; 924(2):133-40. DOI: 10.1016/s0006-8993(01)03058-x. View

17.

Casley C, Canevari L, Land J, Clark J, Sharpe M . Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem. 2002; 80(1):91-100. DOI: 10.1046/j.0022-3042.2001.00681.x. View

18.

Walsh D, Klyubin I, Fadeeva J, Cullen W, Anwyl R, Wolfe M . Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002; 416(6880):535-9. DOI: 10.1038/416535a. View

19.

Dodart J, Bales K, Gannon K, Greene S, DeMattos R, Mathis C . Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002; 5(5):452-7. DOI: 10.1038/nn842. View

20.

Dahlgren K, Manelli A, Stine Jr W, Baker L, Krafft G, LaDu M . Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002; 277(35):32046-53. DOI: 10.1074/jbc.M201750200. View